LaborDr.Merk - Labor Dr. Merk in Ochsenhausen, Germany
Labor Dr.Merk, Lab Dr.Merk, Laboratory Dr.Merk, Laboratory Ochsenhausen, Laboratory Germany, contract research organization Germany, contract development and manufacturing organization Germany, CRO Germany, CRO Ochsenhausen, CDMO Germany, pharmaceutical industry, pharmaceutical industry ochsenhausen, pharmaceutical industry germany, medical device manufactures, contract manufactuig, biosafety testing, vaccine retesting, european market, testing of efficacy of disinfectans, bioassay development, R&D, GMP approved facilities labor germay, expert teams labor germany, lab europe, CRO europe, CMO europe
5
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-5,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,footer_responsive_adv,qode-child-theme-ver-1.0.0,qode-theme-ver-13.6,qode-theme-bridge,disabled_footer_top,wpb-js-composer js-comp-ver-6.6.0,vc_responsive

Welcome at Labor Dr. Merk & Kollegen GmbH

As a CRO and CDMO we offer comprehensive know-how for the pharmaceutical industry and for medical device manufacturers.
Whether you are looking for services in contract manufacturing, biosafety testing, vaccine retesting for the European market, testing of efficacy of disinfectants, bioassay development or a strong partner for your R&D project – we’ve got you covered! Relying on over 40 years of experience, our GMP approved facilities and our expert teams we will support you.

Services

Besides our services in contract manufacturing, Labor Dr. Merk & Kollegen GmbH offers a wide range of testing services in the fields of virology, microbiology, immunology and toxicology.

Manufacturing

As a full CDMO with end-to-end process development, manufacturing with analytical characterization and regulatory support, Labor Dr. Merk & Kollegen GmbH also offers process GMP manufacturing of viral gene therapeutics, oncolytic viral therapeutics and vaccines.

Services

Besides our services in contract manufacturing, Labor Dr. Merk & Kollegen GmbH offers a wide range of testing services in the fields of virology, microbiology, immunology and toxicology.

Manufacturing

As a full CDMO with end-to-end process development, manufacturing with analytical characterization and regulatory support, Labor Dr. Merk & Kollegen GmbH also offers process GMP manufacturing of viral gene therapeutics, oncolytic viral therapeutics and vaccines.

Development

As a CRO and CDMO with more than 40 years of relevant experience, Labor Dr. Merk & Kollegen GmbH is a strong partner for your R&D projects.

Company

Since 1971, Labor Dr. Merk & Kollegen GmbH has evolved into a diversified testing laboratory and CDMO. We provide process development and GMP manufacturing of viral gene therapeutics, oncolytic viral therapeutics and vaccines, as well as testing services in virology, microbiology, immunology.

Development

As a CRO and CDMO with more than 40 years of relevant experience, Labor Dr. Merk & Kollegen GmbH is a strong partner for your R&D projects.

Company

Since 1971, Labor Dr. Merk & Kollegen GmbH has evolved into a diversified testing laboratory and CDMO. We provide process development and GMP manufacturing of viral gene therapeutics, oncolytic viral therapeutics and vaccines, as well as testing services in virology, microbiology, immunology.

Career

Do you enjoy working in small project teams with flat hierarchies? We are always looking for motivated people to join our team!

Contact

Do you have a question or want to work with us? Then please don’t hesitate to contact us via phone, email or using the form below. We will be in touch as soon as possible!

Career

Do you enjoy working in small project teams with flat hierarchies? We are always looking for motivated people to join our team!

Contact

Do you have a question or want to work with us? Then please don’t hesitate to contact us via phone, email or using the form below. We will be in touch as soon as possible!

Testimonials

read more

News

        Pressemitteilung englisch

        Pressemitteilung deutsch

March 15, 2021 – Transaction closing:
Boehringer Ingelheim acquires Labor Dr. Merk & Kollegen

 

Boehringer Ingelheim and Labor Dr. Merk & Kollegen today announced the transaction closing for the acquisition of Labor Dr. Merk & Kollegen by Boehringer Ingelheim. Following the signing of the agreement for the acquisition in December 2020, the approval of the competition authorities in Germany as well as further formalities for the conclusion of the deal have now been completed.
With Labor Dr. Merk & Kollegen, Boehringer Ingelheim establishes a fully integrated expertise hub for the development and clinical manufacturing of therapeutic viruses.
Manufacturing Authorization

 

In August 2019 LMK successfully passed an inspection by the competent authority Regierungspräsidium Tübingen which ended now in the permission to manufacture an oncolytic virus with immune-stimulatory cargo. So LMK holds now a Manufacturing Authorization for a Drug Substance in the context of ATMPs („Advanced Therapy Medicinal Products“) according to the German Drug Law § 15 Abs. 3a S.1 Nr.6.
FDA inspection successfully passed

 

In September 2018 LMK successfully passed an extensive inspection by the FDA. We owe this success to our highly competent and professional staff. The authority’s expectations were met in full, after assessing LMK’s laboratory facilities and quality assurance system against strict cGMP standards. In the closing meeting the FDA inspector emphasized his appreciation for LMK’s comprehensive and coherent data as well as for our well established procedures to secure data integrity.
March 15, 2021 – Transaction closing:
Boehringer Ingelheim acquires Labor Dr. Merk & Kollegen

 

Boehringer Ingelheim and Labor Dr. Merk & Kollegen today announced the transaction closing for the acquisition of Labor Dr. Merk & Kollegen by Boehringer Ingelheim. Following the signing of the agreement for the acquisition in December 2020, the approval of the competition authorities in Germany as well as further formalities for the conclusion of the deal have now been completed.
With Labor Dr. Merk & Kollegen, Boehringer Ingelheim establishes a fully integrated expertise hub for the development and clinical manufacturing of therapeutic viruses.

Manufacturing Authorization

In August 2019 LMK successfully passed an inspection by the competent authority Regierungspräsidium Tübingen which ended now in the permission to manufacture an oncolytic virus with immune-stimulatory cargo. So LMK holds now a Manufacturing Authorization for a Drug Substance in the context of ATMPs („Advanced Therapy Medicinal Products“) according to the German Drug Law § 15 Abs. 3a S.1 Nr.6.
FDA inspection successfully passed

 

In September 2018 LMK successfully passed an extensive inspection by the FDA. We owe this success to our highly competent and professional staff. The authority’s expectations were met in full, after assessing LMK’s laboratory facilities and quality assurance system against strict cGMP standards. In the closing meeting the FDA inspector emphasized his appreciation for LMK’s comprehensive and coherent data as well as for our well established procedures to secure data integrity.

Our customer